www.nature.com/npjvaccines

REVIEW ARTICLE OPEN The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin ✉ ✉ Junli Li 1,2,3,4, Lingjun Zhan1,2,3,4 and Chuan Qin 1,2,3,4

Bacillus Calmette–Guérin (BCG), the only vaccine proven to be effective against (TB), is the most commonly used vaccine globally. In addition to its effects on mycobacterial diseases, an increasing amount of epidemiological and experimental evidence accumulated since its introduction in 1921 has shown that BCG also exerts non-specific effects against a number of diseases, such as non-mycobacterial , allergies and certain malignancies. Recent Corona Virus Disease 2019 (COVID-19) outbreak has put BCG, a classic vaccine with significant non-specific protection, into the spotlight again. This literature review briefly covers the diverse facets of BCG vaccine, providing new perspectives in terms of specific and non-specific protection mechanisms of this old, multifaceted, and controversial vaccine. npj (2021) 6:14 ; https://doi.org/10.1038/s41541-020-00278-0

INTRODUCTION infections observed in children after receiving BCG vaccina- 17–20 Bacillus Calmette–Guérin (BCG), a live-attenuated bacterial tion . Clinical evidence also suggests that BCG may be 1234567890():,; effective against infections caused by viral pathogens, such as vaccine derived from Mycobacterium bovis was originally – 1 respiratory syncytial virus21,22, human papilloma virus23 25,and isolated in 1902 from a cow with tuberculosis (TB) .Theisolate 26 was cultured continuously for >230 generations for 13 years herpes simplex virus . Moreover, an increasing number of (1908–1921) to generate a mutant strain with weakened animal studies using mouse models have demonstrated the virulence but with high immunogenicity2. First used in humans effects of BCG on secondary viral infections. In two separate studies, mice immunized with BCG have been shown to exhibit a in 1921, BCG vaccine has been included in the infant fi fl immunization programs by the World Health Organization signi cantly lower titer of in uenza A virus (H1N1), resulting in a decreased level of inflammation and lung injury, compared with (WHO) since 1974. As of 2018, BCG has been used within the 27,28 national vaccination program of 180 countries or territories in those without BCG immunization . Furthermore, other studies have reported that BCG-vaccinated animal models or Asia, Africa, Europe, and America, with a coverage range of over 3–5 humans appeared to be more resistant to various viruses, 90% . Since the 1920s, the original BCG strain has been – including herpes simplex virus types 1 and 229 31,sendaivirus32, shipped to 20 different international sites, where the vaccine Japanese encephalitis virus33, encephalomyocarditis virus34,35, was repeatedly sub-cultured under different conditions. This has and ectromelia virus36,37, or to non-communicable diseases, given rise to diverse licensed BCG formulations that are distinct 38 39 40 6–8 such as leukemia , allergy , and childhood diabetes . in live mycobacteria content and in genetic composition . Remarkably,BCGcanbeusedasanexpressionvectorfor Currently, the most widely used strains for BCG vaccine recombinant antigens to develop novel vaccines for pathogenic production globally include French Pasteur strain (Pasteur bacteria and viruses41–45,aswellasforcancerimmunother- 1173P2), Denmark 1331 strain (Danish 1331), Brazil strain (BCG apy38,46,47. Clearly, BCG cannot be regarded as a vaccine with Mearou RJ), Russian strain (Moscow-368), Bulgarian substrain only “SpecificEffects” for unilateral prevention of TB. Hence, 9,10 (Sofia SL222), and the Japan 172 strain (Tokyo 172-1) . further understanding on the possible “NSEs” of BCG is As one of the oldest and most widely used vaccines in the required. world, BCG has been administered for nearly a century, with more than four billion of BCG-vaccinated individuals globally11. In most countries, BCG is administered to newborns a few hours CLINICAL CHARACTERIZATION OF BCG VACCINATION or days after birth, and it has been shown to exhibit a protective The safety of BCG has remained as the primary concern regardless efficacy of 73% and 77%, respectively, against TB meningitis and of whether it is used for immune prevention or immunotherapy48. 12–16 miliary TB . Although BCG was specifically developed as a Adverse reactions in children owing to BCG vaccination have been vaccine for TB, numerous studies have shown that BCG has the well reported in countries that routinely administer BCG49. ability to induce the so-called Non-Specific Effects (NSEs) that Complications arising from BCG vaccination can be either mild provide effective protection against other infectious diseases. or severe50. Immune-compromised individuals with conditions Several epidemiological studies conducted in TB endemic such as severe comprehensive immune deficiency, cellular countries have demonstrated that immunization of neonates immune deficiency, chronic granulomatous disease, IL-12 and with BCG can lower neonatal mortality by 50%17, which may be IFN-γ-mediated immune impairment51 often show more-severe attributed to the decreased likelihood of sepsis and respiratory reactions to BCG vaccine, and should therefore avoid BCG

1NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021, P.R. China. 2Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious, Beijing 100021, P.R. China. 3Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing 100021, P.R. China. 4Tuberculosis Center, Chinese Academy of Medical Sciences (CAMS), ✉ Beijing 100021, P.R. China. email: [email protected]; [email protected]

Published in partnership with the Sealy Institute for Vaccine Sciences J. Li et al. 2 vaccination. Other factors that may contribute to the development internalized by DCs can live up to 2 weeks inside these cells68, of adverse reactions include evaluation criteria employed, potency triggering the upregulation of costimulatory molecules and the and dosage of the vaccine strain used, number of immunization production of immune-polarizing cytokines, which are charac- applied, route of delivery, age and immune status of the terized by an increased expression level of CD40, CD80, CD83, vaccinated individual and the skills of the operator administering and CD8669,70. On the other hand, BCG can be phagocytosed the vaccine. and degraded by macrophages, giving rise to immunogenic components of BCG cell wall skeleton, including covalently 66 Normal reactions to BCG vaccination linked mycolic acid, arabinogalactan, and peptidoglycan that can strongly stimulate an inflammatory response through the BCG, as a live bacterial vaccine, can inevitably disseminate beyond 69,71–73 the vaccination site and regional lymph nodes to various parts of activation of different pattern recognition receptors (PRRs) . During the recognition of BCG, whilst the signaling of Toll-like the body under certain conditions. About 2 weeks after BCG receptor (TLR) 2 is triggered via mycobacterial cell wall lipoglycans vaccination, an indurated area with an average diameter of and lipids, such as lipomannan (LM); the signaling of TLR4 ~10 mm typically occurs at the injection site, followed by redness, triggered via other mycobacterial proteins, such as multiple heat- swelling, suppuration, and spontaneous ulceration, which turns – shock proteins and glycoproteins66,74 77. It has been shown that into a crust that falls off on its own after healing in ~6–12 weeks, BCG CpG-DNA can activate intracellular TLR9 in DCs and forming a small permanent scar, commonly known as the “BCG macrophages, resulting in cell activation and the production of Scar”. It takes about 2 or 3 months after BCG vaccination to IL-12, TNF-α, and MCP-1, a crucial mediator of Th1 immune develop a “BCG Scar” without any systemic adverse reactions. It is – response78 82. Likewise, complement receptors CR3 and CR4, worth noting that a small number of individuals receiving BCG nucleotide-binding oligomerization domain (NOD)-like receptors vaccination have been reported to result in slight swelling of the and C-type lectins have been shown to interact with bacterial cell axillary lymph nodes on the same side of the vaccination site52. wall components and participate in the recognition and Generally speaking, the reactions described above are normal 71,83,84 internalization of BCG . Furthermore, studies on BCG- after BCG vaccination, which are self-limiting without requiring immunized adults have demonstrated reprogramming of mono- any special medical treatment. cyte precursors with higher expression of PRRs and greater reactivity to stimuli, such as TLR agonists. Adverse reactions to BCG vaccination

1234567890():,; BCG is the most widely used vaccine globally with an excellent Adaptive immune protection overall safety record. Adverse reactions and complications after Antigen-presenting cells such as DCs, macrophages, and B cells BCG vaccination mainly include mild and transient fever (that – 53 present BCG-derived antigen peptides to major histocompat- alleviates spontaneously after 1 2 days), injection site abscesses ibility complex (MHC) molecules and primary T cells located in (with a diameter of >10 mm that heal in >12 weeks), lymphade- 54 the nearest secondary lymphoid tissue or spleen to initiate an nitis, TB skin rash (such as scleroderma erythema, scrotal lichen, adaptive immune response85 (Fig. 1B). Activated DCs at the BCG and TB papules necrosis that occur between 10 days and 2 months 55,56 inoculation site migrate to the draining lymph nodes, and after BCG vaccination), osteomyelitis , and systemic dissemi- α 57 subsequently secrete TNF- , IL-6, and IL-12 to activate both nated BCG . It has been reported that ~1 in 2500 CD4+ and CD8+ Tcells86–88. Activated CD4+ and CD8+ Tcells recipients of BCG vaccine shows localized BCG-associated mild produce high levels of IFN-γ, which ultimately increases the anti- complications; while one in 100,000 individuals exhibits dissemi- 85,89,90 51,58,59 mycobacterial activity of macrophages . This explains the nated severe complications . As the formation of abscess increased sensitivity to TB in humans with IFN-γ mutations91 and after vaccination is usually self-limiting and can be resolved in mice with IFN-γ gene disrupted91. At the same time, the without the need for treatment, only a small number of patients enhancement of antigen-specific T-cell response is co-stimulated require hospitalization and special procedures. BCG lymphadeni- 92 49,60–63 by neutrophils and activated DCs . Studies have shown that in tis, the most common side effect that manifests as local newborns, a large number of BCG-specificCD4+ and CD8+ lymph node enlargement can form pustules, ulceration, suppura- T cells can be detected in peripheral blood 10 weeks after BCG tion, and other clinical abnormalities such as caseous, abscess, and vaccination. In addition, higher levels of IFN-γ, Granzyme, TNF-α, – – sinus. Statistical analyses have shown that 30% 80% of BCG and IL-2 can be detected in the serum93 95.Inthedevelopment 64 – lymphadenitis can have purulent changes , and that ~15% 30% of BCG or TB-related vaccines, the dominant concept of of non-suppurative lymphadenitis can progress into purulent 65 infectious disease immunology lies within the Th1/Th2 para- lymphadenitis . In addition, unexplained change in urine color digm, in which helper T (Th) cells are assigned an exclusive has been reported as another abnormal reaction after BCG division of labor96. According to this paradigm, whilst Th1 cells vaccination. Generally, the urine color turns orange on the second protect the host from intracellular pathogens (including Myco- day after vaccination and subsequently recovers on its own in bacterium tuberculosis, MTB), Th2 cells protect the host against 65 ~1 week , hence no intervention is required. It is worth noting extracellular pathogens96. Therefore, in the case of TB, IFN-γ that a very small number of BCG recipients may develop allergic secreted by Th1 cells has been used as a criterion for evaluating purpura, anaphylactic shock, immune thrombocytopenia, and the protective immunity against BCG. However, there is a lack of lichenoid skin lesions after vaccination. Although the incidence knowledge in understanding the BCG-induced immune protec- rate of the complications outlined above has been reported to be tion and TB immunology. Therefore, further studies are required low, prompt symptomatic treatment is required, which may to show that IFN-γ is indeed the correct marker of immune include systemic anti-TB treatment if required. protection induced by BCG. The role of humoral immunity in TB is often neglected66. SPECIFIC EFFECTS OF BCG AGAINST TB Therefore, the response of B cells to BCG vaccination has also been ignored. However, since recent studies have indicated that Innate immune protection antibodies have a role in the protection against TB, there has As a complex vaccine consisting live-attenuated mycobacterium, been a growing research interest in determining their relevance BCG causes local infection and immune activation at the site of to vaccine development. In fact, potential mechanisms of administration, where resident monocytes, macrophages, and antibody-mediated immunity against MTB include enhanced dendritic cells (DCs) interact with the bacillus66,67 (Fig. 1A). BCG phagocytosis, increased phagolysosome formation, bacterial

npj Vaccines (2021) 14 Published in partnership with the Sealy Institute for Vaccine Sciences J. Li et al. 3

Fig. 1 Immune response elicited after BCG vaccination-specific effects for MTB. After BCG vaccine is injected intracutaneously, monocytes, macrophages, and DCs recognize the BCG at the vaccination site and form a strong immune response. A BCG is recognized and internalized by DCs or macrophages. The cell wall or other components of BCG act as PRRs that bind to different ligands, upregulate costimulatory molecules of stimulated cells, and activate anti-TB innate immune response. B Activated DC cells migrate to lymph nodes to activate mycobacterial specific CD4+ and CD8+ T cells with a Th1 profile, and subsequently induce the secretion of high levels of cytokines, such as IFN-gamma and granzyme. At the same time, B cells that respond to BCG antigens lead to the production of memory cells, plasma cells, and antigen-specific antibodies. Figure was created using BioRender. neutralization, enhanced inflammasome activation, and that antibody effector functions may play a role in infection enhanced cytotoxic natural killer (NK) cell activity. For example, control103. Moreover, IgA produced due to vaccination from a the formation of bacterial–antibody complexes has been shown different route (intranasal vaccination) has been shown to form to cause increased processing and presentation of MTB antigens mucosal immunity that can also prevent TB infection104.These by phagocytes, which in turn increases T-cell activation and antibodies can neutralize and eliminate pathogens, and activate 97 enhances cytotoxic responses . It has been shown that B cells immune responses by regulating the secretion of cytokines, such can also regulate neutrophilia during BCG vaccination by as TNF-α and IL-1β105. modulating IL-17 response, and that a vigorously increased level of early neutrophil can impair the initiation of CD4+ Tcellsby affecting the migration of DCs to draining lymph nodes, and eventually trigger Th1 immune response that is not conducive to NSES MECHANISM OF BCG antibody production98. A clinical study on BCG has found that, Several mechanisms by which BCG provides NSEs protection compared with that of unvaccinated volunteers, the number of fi against respiratory infections have been a subject of active PPD-speci c memory B cells in PBMCs of BCG-vaccinated is fi significantly higher, but they lacked B-cell reactivity to ESAT-6 or investigation. It has been hypothesized that these non-speci c fi fi CFP-1099. It has been shown that B-cell response induced within bene ts may protect against unrelated infections. The rst “ ” 4–8 weeks after BCG vaccination can increase the production of mechanism, heterologous T-cell immunity is mediated by IgG and induce long-lived memory B cells99,100.Anantibody heterologous T-cell memory responses to provide cross- 106 response to Ag85 complex has been found to be associated with protection . The second mechanism, “trained immunity” relies superior outcome in a cohort of MTB-infected Mexican on reprogramming of innate immune cells that confer non- Indians101. Similarly, low-titer antibodies targeting the surface specific immune memory to innate immune responses107.In glycolipid lipid arabinomannan of MTB have been shown to be addition, other mechanisms include bystander cells and anti- associated with the distribution of TB in children102, indicating bodies/cross-reactive TCR.

Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021) 14 J. Li et al. 4

Fig. 2 BCG vaccination induces trained immunity. BCG vaccination induces trained immunity of monocytes/macrophages, leading to increased epigenetic reprogramming and host defense capabilities. Chromatin rearrangement induces a “trained” state in monocytes, hence enhancing the effectiveness of innate immune response upon exposure to non-specific pathogens (respiratory syncytial virus or yellow fever virus), and inducing the secretion of proinflammatory cytokines, such as IL-6, IL-1β, and TNF-alpha. However, whether this “training process” can prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs further validation. H3K4me3: trimethylation of lysine at position 4 on histone 3; H3K9me3: trimethylation of lysine at position 9 on histone 3. Figure was created using BioRender.

Heterologous T-cell immunity of BCG vaccination functional adaptive immune responses118,119. Trained immunity Heterologous T-cell immunity is based on the effects exerted by the is non-specific innate immune protection, formed by monocytes/ adaptive immune system, where primarily T cells mediate the cross- macrophages and NK cells of the innate immune system, which reactivity between vaccine-related and vaccine-unrelated antigens, responds more rapidly and strongly against secondary infections giving rise to NSEs in vaccines. As such, T-cell vaccine responses may of different microorganisms, depending on the nature and 108 be impacted or modified through exposures to previously infected concentration of the ligand , without involving T and B 26,107,120,121 pathogens106,108,109. Although antigen cross-reactivity may provide cells . Originally identified in NK cells, trained immu- some beneficial protective immunity in some cases, the reaction nity has been shown to be BCG-inducible in monocytes. may cause severe immunopathological damage in other cases. Epigenetic reprogramming of monocytes in infection or Therefore, T-cell-mediated heterologous immunity provides a immune sites has been shown as one of the molecular possible biological mechanism that can affect the immune response mechanisms that induces trained immunity (Fig. 2). These fi in subsequent unrelated infections. This also explains how a vaccine monocytes undergo histone modi cations (such as methylation, can adversely affect the outcome of secondary infections. The acetylation, deamination, and proline isomerization) at the fl molecular similarity between BCG antigens and viral antigens, such promoter sites of genes encoding in ammatory cytokines, as epitopes, can induce the production of a population of memory B resulting in their ability to respond to new stimuli continuously, and T cells that recognize both BCG and other pathogens. For leading to an increasingly active immune response upon fi example, BCG vaccination can protect mice from vaccinia virus reactivation. As histone modi cation is highly dynamic and can infection by increasing the IFN-γ produced by CD4+ cells110.In be changed within minutes, reprogrammed monocytes can act human healthy volunteers, the enhancement of non-specificTh1 very rapidly to confer resistance against other pathogens. fi and Th17 responses can still be observed within 1 year after BCG Epigenetic modi cation in the immune system involves cell fl 108,122–125 vaccination111. Similarly, in animal experiments, non-targeted differentiation, in ammation and autoimmune responses . antigens have the effect of activating specificCD4+ and CD8+ In supporting the occurrence of trained immunity in the context of memory cells, thereby regulating the response of Th1 and Th17 to BCG immunization, it has been observed that monocytes from non-mycobacterial secondary infections. In addition, BCG has been adults with BCG vaccination, compared with those without BCG shown to cause antigen-independent activation of bystander CD4 vaccination exhibit increased expression of various surface 110,112–114 markers related to immune activation, and produce higher and CD8 memory cells . However, this mechanism is β γ α unlikely to explain the diversified protection against different quantities of cytokines, such as IL-1 , IL-6. IFN- , and TNF- upon pathogens through BCG vaccination. More importantly, although exposure to infection of various pathogens. In addition, peripheral heterologous Th1/Th17 immunity may mediate the long-term blood mononuclear cells (PBMCs) have been shown to exhibit an increased histone modification of H3K4me3 and a decreased effects of heterologous immunity, it takes at least a couple of histone modification of H3K9me3, both associated with the weeks to be developed, hence highly unlikely to be responsible for promoters of proinflammatory cytokines TNF-α, IL-6, and TLR4 the immediate effects observed in perinatal immunity18,106. for transcription activation126,127. Metabolite reprogramming is another molecular mechanism Trained immunity of BCG vaccination that induces trained immunity (Fig. 2). Some studies have found Many organisms lacking adaptive immunity, such as plants115 that, after BCG inoculation, the level of glycolysis metabolism is and insects116,117 manifest robust immune memory after being increased in human monocytes, shifting the cellular metabolic exposed to infections. Similar adaptive features of innate process from oxidative phosphorylation to aerobic glycolysis. immunity have also been demonstrated in mice devoid of Through dectin-1 receptor, β-glucan detected by monocytes/

npj Vaccines (2021) 14 Published in partnership with the Sealy Institute for Vaccine Sciences J. Li et al. 5 macrophages can activate the PI3K (phosphoinositide 3 kinase)- symptoms. However, it is unclear whether older individuals are AKT-mTOR (mammalian target of rapamycin)-HIF-1α (hypoxia- able to maintain a pool of trained monocytes many years after inducible factor-1α) pathway, which subsequently induces a receiving BCG vaccination. Similarly, in some high-risk individuals, metabolic shift toward aerobic glycolysis; increases glutamino- initial defective antiviral response may lead to an increased viral lysis that replenishes the tricarboxylic acid cycle; activates the load that stimulates ineffective systemic inflammation and causes cholesterol synthesis pathway; and blocks the itaconate path- serious illness. way119,128–132. Consequently, metabolites such as fumarate, There is currently a large amount of literature that review the succinate, and mevalonate accumulate and then become the possibility of utilizing BCG to prevent COVID-19 based on the cofactors of epigenetic modifiersandactasamplifiers of trained epidemiological analysis of BCG vaccination policy and the immunity130,133. BCG vaccine has been shown to induce incidence of COVID-19 in different countries. Epidemiological genome-wide epigenetic changes, including the monomethyla- evidence indicates that countries with national universal BCG tion and trimethylation of histone (H) 3 lysine (K) 4/9, and the vaccination programs for TB prevention, compared with those acetylation of H3K27 at promoters and enhancers of genes without such programs, have a much lower incidence rate of associated with metabolic, immune and host defense path- severe COVID-19 and mortality. However, it is undeniable that ways119,127,134. Hence, trained monocytes/macrophages produce different countries have differences in COVID-19 detection increased levels of cytokines, such as TNF-α,IL-1β, and IL-6, when capabilities, treatment efficacies and isolation policies, as well challenged with microbial constituents119,127,130,135. as in economy status, demographics, and population genetic structures. It is precisely because of the above-mentioned various constraints that the results of this epidemiological NSES OF BCG AGAINST INFECTIOUS DISEASES OTHER THAN TB investigation can only be used to explain the possibility of this BCG may also reduce the acquisition of non-mycobacterial hypothesis. BCG vaccine has been in short supply owing to high infections and decrease the risk of heterologous infections demand and manufacturing restrictions. The global BCG short- arising from various pathogens, including bacteria, viruses, and age in 2016 and 2019 has led to changes in the management of malarial parasites. Different clinical studies have been carried BCG for the treatment of bladder cancer. Hence, many countries out based on the NSEs of BCG (Table 1). However, it is worth have decreased the dosage and limited the usage of BCG. In noting that besides the causative pathogens, there are many order to prevent the over-consumption of BCG vaccine, and to factors can potentially contribute to the heterologous effects of avoid the false impression that BCG vaccine can provide BCG vaccination. Some studies have suggested that diphtheria- protection against COVID-19, the WHO has recently warned that tetanus-pertussis vaccine may affect the impact of BCG on BCG should not be used indiscriminately in COVID-19 patients childhood mortality, implicating that other vaccines may until appropriate evidence is available138.Itiscommendablethat modulate the NSEs of BCG immunization. In addition, patient more than a dozen of new clinical trials of BCG vaccine for age, gender and time post-BCG vaccination may also be the COVID-19 have been conducted on healthcare workers and the contributing factors of NSEs. The manisfestation of hetero- elderly in countries such as Australia, USA, and Netherlands. logous effects of BCG may be the most apparent for neonates These clinical trials may unveil the efficacy of BCG against vaccinated at birth. Similarly, studies have shown that in young COVID-19 (Table 2). calves, the effect of BCG-induced innate training in circulating immune populations can last three months136. The gradual waning of BCG heterologous protective effect can be explained NON-SPECIFIC IMMUNOTHERAPY USING BCG by the fact that as infants grow older, they become exposed to Besides offering specific prevention against TB or non-specific pathogens more frequently, with the resulting development of prevention against other infectious diseases, BCG has also been the classical immunity against infectious diseases eventually recognized to exert a non-specific therapeutic effect in patients overcoming the heterologous beneficial effects of BCG. with non-muscle invasive bladder cancer (NMIBC)139.First introduced in 1976 for clinical application in urology, the use of BCG in therapy was subsequentlyapprovedbytheFoodand CAN BCG CONFER PROTECTION AGAINST COVID-19? Drug Administration (FDA) for the treatment of superficial The Corona Virus Disease 2019 (COVID-19) pandemic has bladder cancer in 1990140. Several guidelines, including those prompted an urgent need for novel vaccination or interventions outlined by the American Urological Association (AUA)141,the to lower the disease morbidity and mortality globally. Promising International Bladder Cancer Group (IBCG)142 and the Interna- new trials aiming to ascertain whether this commonly used “old tional Consultation on Urological Diseases (ICUD)143 have vaccine” is effective against “new disease” COVID-19 have been recommended BCG for NMIBC immunotherapy. BCG is still conducted. BCG has been well documented in the infectious being considered as one of the standard interventions in disease literature for its ability to induce NSEs against unrelated alleviating NMIBC progression and recurrence144,145. Although conditions. Randomized controlled trials are required to provide BCG has been used for the treatment of NMIBC for nearly 40 direct evidence in order to demonstrate whether BCG vaccination, years, its therapeutic effect requires further investigation. through trained immunity, is capable of providing protection Intravesical instillation of BCG can induce multiple immune against COVID-19 (Fig. 2). In vivo studies have shown that BCG can reactions that result in inflammation and subsequent elimination successfully alleviate yellow fever viremia through epigenetic of tumors146 (Fig. 3). On one hand, although the vast majority of reprogramming of monocytes/macrophages in the human innate the original instillation dose of BCG containing several hundred immune system127. Although BCG has been shown to induce a million mycobacteria is washed out from the bladder, the trained immune response against H7N9 in mouse models, remaining mycobacteria adhere to urothelial and cancer cells subsequent evaluations show that the immune response is not through fibronectin, an extracellular glycoprotein distributed in significantly associated with clinical survival, clinical scores or normal and malignant urothelium147. To initiate an early pulmonary inflammation137. The effectiveness of the NSEs of BCG immune response, antigen processing of APCs regulated by is based on the knowledge that in BCG-vaccinated healthy internalized BCG148 enhances the surface expression of MHC-II individuals, innate antibacterial mechanism can be enhanced by and intercellular cell adhesion molecule-1 (ICAM-1) of bladder the well-trained immune system, which may contribute to the cancer cells47. On the other hand, BCG can initiate a cascade of suppression of virus replication and the decrement of viral load, complex inflammatory events within hours of instillation. A and subsequently result in the alleviation of inflammation and marked increase in the number of leukocytes comprising mainly

Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021) 14 6 p acns(01 14 (2021) Vaccines npj

Table 1. Clinical trials of BCG as a mitigation factor against infectious diseases other than TB.

Pathogens ID Possible Phase Country Time Enrollment Subjects Aims Outcome measures mechanism

Influenza virus NCT02114255 Trained II/III Netherlands May 2014–Sep. 2014 40 Healthy To investigate whether prior BCG ✧ Thrombocyte function. immunity adult (male) vaccination improves the efficacy of ✧ Seroprotection (Influenza antibody titer influenza vaccination in young and/or ≥1:40 or ≥4-fold rise). old healthy volunteers. ✧ Granzyme B, IFN-γ, IL-10, IL-17, and IL-22 by leukocytes ex vivo stimulated with inactivated/live influenza virus. ✧ TNF-α, IL-1β, IFN-γ, IL-10, IL-17, IL-22 by leukocytes ex vivo stimulated with different not-related stimuli. Hepatitis B NCT02444611 Trained NA Australia Mar. 2015–Jun. 2016 185 Child To investigate the effects of BCG and ✧ Cytokine concentrations in response to immunity Hepatitis B vaccine, given at birth, on in vitro stimulation with a range of the neonatal immune responses homologous or heterologous antigens (IL- against non-specific antigens. 1α, IL-1β, MCP-1, MIP-1α, MIP-1β, IFN-γ, IL- 10, MIF, MIG, TNF-α). HIV NCT00331474 Immune I/II South Africa May 2006–Aug. 2009 180 Infant To investigate whether BCG can trigger ✧ BCG-induced cellular immune responses. activation immune responses against HIV, and ✧ Serum antibody responses. whether BCG can regulate the ✧ BCG scarring and TB incidence. spreading of HIV and early progression to AIDS in babies borned from HIV- positive mothers. + NCT02062580 Immune II South Africa Jun. 2010–Apr. 2012 149 Infant To investigate whether routine BCG ✧ Percentage of all CD4 T cells expressing activation immunization of neonates contributes HLA-DR. ✧ + to generalized immune activation in Percent of CD4 T cells expressing Ki-67 al. et Li J. HIV-exposed infants and increased after stimulation in vitro with BCG. rates of disease progression in HIV- infected infants. NCT02606526 Trained III Uganda Jul. 2016– 2200 Infant To investigate whether BCG ✧ Proportion of infants with severe illness. immunity vaccination at birth, in a high-risk HIV- ✧ Production of TNF-α, IL-1β, IL-6 and IFN-γ in exposed can protect infants against response to mycobacterial and non- serious infections other than TB. mycobacterial antigens. ✧ Adverse events and infant . ulse nprnrhpwt h el nttt o acn Sciences Vaccine for Institute Sealy the with partnership in Published Malarial parasites NCT00126217 Trained IV Guinea Jul. 2002–Sep. 2006 2871 Child To investigate whether BCG boosting ✧ Adverse effects. immunity or no boosting have has an effect on ✧ Mortality till 5 years of age and the prevalence of malaria morbidity/parasitaemia within 12 months parasitaemia. after intervention. ✧ Antibody and cellular immune responses 18 months after intervention. NCT00131794 Trained III Guinea Jan. 2003–Dec. 2003 1200 Child Effect of BCG vaccine on morbidity ✧ Incidence of clinical malaria. immunity caused by malaria infection. ✧ Prevalence of malaria parasitemia. NCT02692963 Trained II Netherlands Apr. 2016–Feb. 2017 20 Healthy adult To investigate whether BCG ✧ Frequency and magnitude of adverse immunity vaccination can offer protection events. against malaria in the Controlled ✧ Time to blood stage parasitemia detectable Human Malaria Infection by qPCR. (CHMI) model. ✧ Changes in cellular (innate and adaptive) immune responses. ✧ Changes in plasma cytokine levels. Bordetella pertussis NCT02771782 Trained IV Netherlands Jan. 2015–Jul. 2016 75 Healthy adult To investigate whether BCG ✧ Antibody titers. immunity (female) vaccination modulates an immune ✧ PBMC cytokine response to homologous or response against non-vaccine target heterologous antigens (IL-6, TNF-α, IL-1β, antigens. IL-10, IL-17, IL-22, IFN-γ). Corynebacterium NCT02771782 Trained IV Netherlands Jan. 2015–Jul. 2016 75 Healthy adult To investigate whether BCG ✧ Antibody titers. diphtheria immunity (female) vaccination modulates an immune ✧ T-cell response and B-cell phenotype response against non-vaccine target analysis. antigens. ✧ PBMC cytokine response to homologous or heterologous antigens (IL-6, TNF-α, IL-1β, IL-10, IL-17, IL-22, IFN-γ). ID ClinicalTrials.gov Identifier, NA not available, HLA-DR human leukocyte antigen DR, PBMC peripheral blood mononuclear cell. J. Li et al. 7

Table 2. Ongoing clinical trials of BCG as a mitigation factor against COVID-19.

ID Phase Country Time Enrollment Subjects Sponsor BCG strain

NCT04328441 III Netherlands Mar. 2020 1500 Healthy Adult (HCW) UMC Utrecht Danish strain 1331 NCT04327206 III Australia/Spain Mar. 2020 10078 Healthy Adult (HCW) Murdoch Childrens Research Institute Danish strain 1331 NCT04348370 V USA Apr. 2020 1800 Healthy Adult (HCW) Texas A&M University Tice strain NCT04417335 V Netherlands Apr. 2020 2014 Healthy Adult (≥60 years) Radboud University Danish strain 1331 NCT04362124 III Colombia Apr. 2020 1000 Healthy Adult (HCW) Universidad de Antioquia BCG Liofilizada NCT04350931 III Egypt Apr. 2020 900 Healthy Adult (HCW) Ain Shams University Danish Strain 1331 NCT04373291 III Denmark May 2020 1500 Healthy Adult (HCW) University of Southern Denmark Bandim Health Danish strain 1331 Project NCT04414267 V Greece May 2020 900 Healthy Adult (≥50 years) Hellenic Institute for the Study of Sepsis Moscow strain 361-1 NCT04379336 III South Africa May 2020 500 Healthy Adult (HCW) TASK Applied Science Danish strain 1331 NCT04384549 III France May 2020 1120 Healthy Adult (HCW) Assistance Publique - Hôpitaux de Paris NA NCT04475302 III India Jul. 2020 2175 Healthy Adult (≥60 years) Tuberculosis Research Center, India SII strain NCT04461379 III Mexico Jul. 2020 908 Healthy Adult (HCW) Hospital Universitario Tokyo 172 strain NCT04537663 V Netherlands Aug. 2020 5200 Healthy Adult (≥60 years) UMC Utrecht Danish strain 1331 NCT04369794 V Brazil Aug. 2020 1000 Healthy Adult (≥18 years) University of Campinas NA NCT04534803 III USA Sep. 2020 2100 Healthy Adult (≥60 years) Harvard Medical School Tokyo 172 strain NCT04542330 III Denmark Sep. 2020 1900 Healthy Adult (≥65 years) Bandim Health Project Danish strain 1331 ID ClinicalTrials.gov Identifier, HCW Health Care Workers, NA not available, SII Serum Institute of India.

Fig. 3 Possible mechanism of BCG non-specific immunotherapy in non-muscle invasive bladder cancer. BCG attached to the urothelium is internalized by bladder cancer cells, causing direct cytotoxicity of immune system effectors to kill bladder cancer cells. A BCG attaches to the urothelium via fibronectin and integrin α5β1, and is internalized by bladder cancer cells, owing to oncogenic aberrations that activate macropinocytosis. Following internalization, bladder cancer cells upregulate the expression of MHC-II and ICAM-1. B Various immune cells infiltrate bladder tumor tissues, release large amounts of inflammatory cytokines and chemokines, and change the tumor microenvironment. C Activated immune cells, such as CD4 and CD8 T cells, are cytotoxic to bladder cancer cells. Figure was created using BioRender. granulocytes, and to a lesser degree, macrophages, and IL-8, and IL-17 are released into the urine following BCG therapy, lymphocytes, are detectable in urine149.Inaddition,ithasbeen and that the release of cytokines and chemokines is significantly foundthatawidevarietyofcytokines and chemokines, enhanced after BCG re-administration145,149–163. More impor- including Th1 (INF-γ, IL-2, TNF, and IL-12), Th2 (IL-6 and IL-10), tantly, a large number of neutrophils163–165 and monocytes/

Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021) 14 J. Li et al. 8 macrophages have been found to infiltrate the bladder wall, 11. Whittaker, E., Goldblatt, D., McIntyre, P. & Levy, O. Neonatal immunization: adding additional characteristic cytokines and chemokines to rationale, current state, and future prospects. Front. Immunol. 9, 532 (2018). the tumor microenvironment146,166,167. Histopathologically, post- 12. Colditz, G. A. et al. The efficacy of bacillus Calmette-Guerin vaccination of treatment bladder biopsies in patients treated with BCG reveal newborns and infants in the prevention of tuberculosis: meta-analyses of the 96 – erosioninsuperficial epithelium, and inflammation in submu- published literature. Pediatrics ,29 35 (1995). cosal granulomatous, coupled with edema and noncaseating 13. Miceli, I. et al. Evaluation of the effectiveness of BCG vaccination using the case- control method in Buenos Aires, Argentina. Int. J. Epidemiol. 17, 629–634 (1988). granulomas surrounded by lymphoplasmacytic and eosinophilic 157 14. Trunz, B. B., Fine, P. & Dye, C. Effect of BCG vaccination on childhood tuber- infiltrates . Furthermore, the non-specific anti-tumor effect culous meningitis and miliary tuberculosis worldwide: a meta-analysis and induced by BCG is considered to be a key intervention for NMIBC assessment of cost-effectiveness. Lancet (Lond., Engl.) 367, 1173–1180 (2006). immunotherapy. In particular, the anti-tumor effects mediated 15. Bonifachich, E. et al. Protective effect of Bacillus Calmette-Guerin (BCG) vacci- + + by CD4 T cells and CD8 cytotoxic T lymphocytes have been nation in children with extra-pulmonary tuberculosis, but not the pulmonary well documented. An increased tumor-infiltrating CD4+ T-cell disease. A case-control study in Rosario, Argentina. Vaccine 24, 2894–2899 count and an increased CD4+:CD8+ T-cell ratio have been (2006). demonstrated to be significantly associated with improved 16. Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosis patient response to BCG156 in athymic nude mice168. Recent infection in children: systematic review and meta-analysis. BMJ (Clin. Res. ed.) 349, g4643 (2014). studies have also shown that the main cell subsets of leukocytes 17. Aaby, P. et al. Randomized trial of BCG vaccination at birth to low-birth-weight or neutrophils after repeated BCG instillation produce higher children: beneficial nonspecific effects in the neonatal period? J. Infect. Dis. 204, levels of TNF-related apoptosis-inducing ligand (TRAIL) to 245–252 (2011). provide an additional cytotoxic mechanism, which induces 18. Biering-Sørensen, S. et al. Small randomized trial among low-birth-weight chil- apoptotic cell death in TRAIL receptor-expressing tumor dren receiving bacillus Calmette-Guérin vaccination at first health center con- cells79–82,169. tact. Pediatr. Infect. Dis. J. 31, 306–308 (2012). 19. Roth, A. et al. Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr. Infect. Dis. J. 23, 544–550 SUMMARY AND OUTLOOK (2004). 20. Biering-Sørensen, S. et al. Early BCG-Denmark and neonatal mortality among An increasing number of studies have suggested that BCG infants weighing <2500 g: a randomized Controlled Trial. Clin. Infect. Dis. 65, vaccination can exert non-specific protective effects to prevent 1183–1190 (2017). diseases other than TB, and that BCG may be used as a 21. Stensballe, L. G. et al. Acute lower respiratory tract infections and respiratory therapeutic agent to modulate the cellular immune response in syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination treating bladder cancer. These findings have important implica- for girls community based case-control study. Vaccine 23, 1251–1257 (2005). tions for BCG and other vaccines that may exert similar 22. Wardhana, Rifai, Datau, E. A., Sultana, A., Mandang, V. V. & Jim, E. The efficacy of beneficial heterologous effects. Further studies are required to Bacillus Calmette-Guerin vaccinations for the prevention of acute upper 43 – address how BCG regulates T- and B-cell subpopulations with respiratory tract infection in the elderly. Acta Med. Indonesiana , 185 190 different antigen specificities, as well as how BCG maintains and (2011). 23. Salem, A., Nofal, A. & Hosny, D. Treatment of common and plane warts in promotes the proliferation of memory or effector cells. At the children with topical viable Bacillus Calmette-Guerin. Pediatr. Dermatol. 30, same time the role of innate immune response in mediating the 60–63 (2013). NSEs of BCG requires validation. In addition, it will be 24. Podder, I. et al. Immunotherapy in viral warts with intradermal Bacillus Calmette- meaningful to explore whether other immune cell types may Guerin vaccine versus intradermal tuberculin purified protein derivative: a participate in non-specific immune protection. In summary, double-blind, randomized controlled trial comparing effectiveness and safety in future research findings may improve our understanding on the a tertiary care center in Eastern India. Indian J. Dermatol. Venereol. Leprol. 83, 411 mechanism of BCG in anti-TB, as well as its NSEs in other (2017). infectious diseases. 25. Daulatabad, D., Pandhi, D. & Singal, A. BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area? Dermatol. Ther. 29, 168–172 (2016). Received: 20 September 2020; Accepted: 14 December 2020; 26. Moorlag, S., Arts, R. J. W., van Crevel, R. & Netea, M. G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25, 1473–1478 (2019). 27. Spencer, J. C., Ganguly, R. & Waldman, R. H. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guérin. J. Infect. Dis. 136, 171–175 (1977). REFERENCES 28. Mukherjee, S. et al. Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia. PloS ONE 12, e0180143 (2017). 1. Daniel, T. M. The history of tuberculosis. Respir. Med. 100, 1862–1870 (2006). 29. Floc’h, F. & Werner, G. H. Increased resistance to virus infections of mice 2. Corbel, M. J., Fruth, U., Griffiths, E. & Knezevic, I. Report on a WHO consultation inoculated with BCG (Bacillus calmette-guérin). Ann. Immunol. 127, 173–186 on the characterisation of BCG strains, Imperial College, London 15-16 (1976). December 2003. Vaccine 22, 2675–2680 (2004). 30. Starr, S. E., Visintine, A. M., Tomeh, M. O. & Nahmias, A. J. Effects of immunos- 3. WHO. World Health Organization. Global tuberculosis report 2018. (WHO, Geneva, timulants on resistance of newborn mice to herpes simplex type 2 infection. 2018). Proc. Soc. Exp. Biol. Med. 152,57–60 (1976). 4. Ottenhoff, T. H. & Kaufmann, S. H. Vaccines against tuberculosis: where are we 31. Ikeda, S., Negishi, T. & Nishimura, C. Enhancement of non-specific resistance to and where do we need to go? PLoS Pathog. 8, e1002607 (2012). viral infection by muramyldipeptide and its analogs. Antivir. Res. 5, 207–215 5. McShane, H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos. (1985). Trans. R. Soc. Lond. Ser. B, Biol. Sci. 366, 2782–2789 (2011). 32. Ishihara, C. et al. Suppression of Sendai virus growth by treatment with N alpha- 6. Brosch, R. et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice. Natl. Acad. Sci. USA 104, 5596–5601 (2007). Vaccine 5, 295–301 (1987). 7. Favorov, M. et al. Comparative tuberculosis (TB) prevention effectiveness in 33. Kulkarni, S. et al. Bacillus Calmette-Guérin confers neuroprotection in a murine children of Bacillus Calmette-Guerin (BCG) vaccines from different sources, model of Japanese Encephalitis. Neuroimmunomodulation 23, 278–286 (2016). Kazakhstan. PloS ONE 7, e32567 (2012). 34. Lodmell, D. L. & Ewalt, L. C. Enhanced resistance against encephalomyocarditis 8. Mostowy, S., Tsolaki, A. G., Small, P. M. & Behr, M. A. The in vitro evolution of BCG virus infection in mice, induced by a nonviable Mycobacterium tuberculosis oil- vaccines. Vaccine 21, 4270–4274 (2003). droplet vaccine. Infect. Immun. 19, 225–230 (1978). 9. WHO. V3P database (Data 2017). Available at http://www.who.int/immunization/ 35. Lodmell, D. L. & Ewalt, L. C. Induction of enhanced resistance against ence- programmes_systems/procurement/v3p/platform/en/. Accessed Nov 2017. phalomyocarditis virus infection of mice by nonviable Mycobacterium tuber- 10. Li, J. et al. Tuberculosis vaccine development: from classic to clinical candidates. culosis: mechanisms of protection. Infect. Immun. 22, 740–745 (1978). Eur. J. Clin. Microbiol. Infect. Dis. 39, 1405–1425 (2020).

npj Vaccines (2021) 14 Published in partnership with the Sealy Institute for Vaccine Sciences J. Li et al. 9 36. Suenaga, T., Okuyama, T., Yoshida, I. & Azuma, M. Effect of Mycobacterium 61. Daei Parizi, M., Kardoust Parizi, A. & Izadipour, S. Evaluating clinical course of tuberculosis BCG infection on the resistance of mice to ectromelia virus infec- BCG lymphadenitis and factors affect on it during a 5-year period in Kerman, tion: participation of interferon in enhanced resistance. Infect. Immun. 20, Iran. J. Trop. Pediatr. 60, 148–153 (2014). 312–314 (1978). 62. Sharifi Asadi, P. et al. Clinical, laboratory and imaging findings of the patients 37. Sakuma, T., Suenaga, T., Yoshida, I. & Azuma, M. Mechanisms of enhanced with disseminated bacilli Calmette-Guerin disease. Allergol. Immunopathol. 43, resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus 254–258 (2015). infection. Infect. Immun. 42, 567–573 (1983). 63. Bukhari, E., Alzahrani, M., Alsubaie, S., Alrabiaah, A. & Alzamil, F. Bacillus 38. Morra, M. E. et al. Early vaccination protects against childhood leukemia: a Calmette-Guerin lymphadenitis: a 6-year experience in two Saudi hospitals. systematic review and meta-analysis. Sci. Rep. 7, 15986 (2017). Indian J. Pathol. Microbiol. 55, 202–205 (2012). 39. Thøstesen, L. M. et al. Neonatal BCG vaccination and atopic dermatitis before 64. Kuyucu, N., Kuyucu, S., Ocal, B. & Teziç, T. Comparison of oral erythromycin, local 13 months of age: a randomized clinical trial. Allergy 73, 498–504 (2018). administration of streptomycin and placebo therapy for nonsuppurative Bacillus 40. Rousseau, M. C., El-Zein, M., Conus, F., Legault, L. & Parent, M. E. Bacillus Calmette-Guérin lymphadenitis. Pediatr. Infect. Dis. J. 17, 524–525 (1998). Calmette-Guérin (BCG) vaccination in infancy and risk of childhood diabetes. 65. Singla, A., Singh, S., Goraya, J. S., Radhika, S. & Sharma, M. The natural course of Paediatr. Perinat. Epidemiol. 30, 141–148 (2016). nonsuppurative Calmette-Guérin bacillus lymphadenitis. Pediatr. Infect. Dis. J. 41. Fennelly, G. J., Flynn, J. L., ter Meulen, V., Liebert, U. G. & Bloom, B. R. Recom- 21, 446–448 (2002). binant bacille Calmette-Guérin priming against . J. Infect. Dis. 172, 66. Dockrell, H. M. & Smith, S. G. What have we learnt about BCG vaccination in the 698–705 (1995). last 20 years? Front. Immunol. 8, 1134 (2017). 42. Yu, J. S. et al. Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits 67. Moliva, J. I., Turner, J. & Torrelles, J. B. Immune responses to bacillus Calmette- human immunodeficiency virus type 1 envelope-specific T lymphocytes at Guérin vaccination: why do they fail to protect against Mycobacterium tuber- mucosal sites. Clin. Vaccine Immunol. 14, 886–893 (2007). culosis? Front. Immunol. 8, 407 (2017). 43. Chapman, R., Stutz, H., Jacobs, W. Jr., Shephard, E. & Williamson, A. L. Priming 68. Jiao, X. et al. Dendritic cells are host cells for mycobacteria in vivo that trigger with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and innate and acquired immunity. J. Immunol. 168, 1294–1301 (2002). boosting with recombinant MVA induces a robust T cell response in mice. PloS 69. Tsuji, S. et al. Maturation of human dendritic cells by cell wall skeleton of ONE 8, e71601 (2013). Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like recep- 44. Palavecino, C. E., Céspedes, P. F., Gómez, R. S., Kalergis, A. M. & Bueno, S. M. tors. Infect. Immun. 68, 6883–6890 (2000). Immunization with a recombinant bacillus Calmette-Guerin strain confers pro- 70. Dowling, D., Hamilton, C. M. & O’Neill, S. M. A comparative analysis of cytokine tective Th1 immunity against the human metapneumovirus. J. Immunol. 192, responses, cell surface marker expression and MAPKs in DCs matured with LPS 214–223 (2014). compared with a panel of TLR ligands. Cytokine 41, 254–262 (2008). 45. Soto, J. A. et al. Recombinant BCG vaccines reduce pneumovirus-caused airway 71. Kleinnijenhuis, J., Oosting, M., Joosten, L. A., Netea, M. G. & Van Crevel, R. Innate pathology by inducing protective humoral immunity. Front. Immunol. 9, 2875 immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011, (2018). 405310 (2011). 46. Pfahlberg, A. et al. Inverse association between melanoma and previous vac- 72. Azuma, I., Ribi, E. E., Meyer, T. J. & Zbar, B. Biologically active components from cinations against tuberculosis and smallpox: results of the FEBIM study. J. invest. mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and Dermatol. 119, 570–575 (2002). component P3. J. Natl. Cancer Inst. 52,95–101 (1974). 47. Ikeda, N., Toida, I., Iwasaki, A., Kawai, K. & Akaza, H. Surface antigen expression 73. Chatterjee, D. The mycobacterial cell wall: structure, biosynthesis and sites of on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG drug action. Curr. Opin. Chem. Biol. 1, 579–588 (1997). internalization into tumor cells. Int. J. Urol. 9,29–35 (2002). 74. Quesniaux, V. J. et al. Toll-like receptor 2 (TLR2)-dependent-positive and TLR2- 48. Murphy, D., Corner, L. A. & Gormley, E. Adverse reactions to Mycobacterium independent-negative regulation of proinflammatory cytokines by myco- bovis bacille Calmette-Guérin (BCG) vaccination against tuberculosis in humans, bacterial lipomannans. J. Immunol. 172, 4425–4434 (2004). veterinary animals and wildlife species. Tuberculosis (Edinb., Scotl.) 88, 344–357 75. Bulut, Y. et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll- (2008). like receptor pathways to activate pro-inflammatory signals. J. Biol. Chem. 280, 49. Bolger, T., O’Connell, M., Menon, A. & Butler, K. Complications associated with 20961–20967 (2005). the bacille Calmette-Guérin vaccination in Ireland. Arch. Dis. Child. 91, 594–597 76. Kim, K. et al. Mycobacterium tuberculosis Rv0652 stimulates production of (2006). tumour necrosis factor and monocytes chemoattractant protein-1 in macro- 50. Govindarajan, K. K. & Chai, F. Y. BCG adenitis-need for increased awareness. phages through the Toll-like receptor 4 pathway. Immunology 136, 231–240 Malays. J. Med. Sci. 18,66–69 (2011). (2012). 51. Afshar Paiman, S., Siadati, A., Mamishi, S., Tabatabaie, P. & Khotaee, G. Dis- 77. Jung, S. B. et al. The mycobacterial 38-kilodalton glycolipoprotein antigen seminated Mycobacterium bovis infection after BCG vaccination. Iran. J. Allergy activates the mitogen-activated protein kinase pathway and release of proin- Asthma Immunol. 5, 133–137 (2006). flammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. 52. Barari-Savadkouhi, R., Shour, A. & Masrour-Roudsari, J. A study of the incidence Infect. Immun. 74, 2686–2696 (2006). of BCG vaccine complications in infants of Babol, Mazandaran (2011-2013). 78. Li, J. et al. Unmethylated CpG motif-containing genomic DNA fragment of Casp. J. Intern. Med. 7,48–51 (2016). Bacillus calmette-guerin promotes macrophage functions through TLR9- 53. Venkataraman, A., Yusuff, M., Liebeschuetz, S., Riddell, A. & Prendergast, A. J. mediated activation of NF-κB and MAPKs signaling pathways. Innate Immun. Management and outcome of Bacille Calmette-Guérin vaccine adverse reac- 26, 183–203 (2020). tions. Vaccine 33, 5470–5474 (2015). 79. Tokunaga, T., Yamamoto, T. & Yamamoto, S. How BCG led to the discovery of 54. Muto, J., Kuroda, K. & Tajima, S. Papular tuberculides post-BCG vaccination: case immunostimulatory DNA. Jpn. J. Infect. Dis. 52,1–11 (1999). report and review of the literature in Japan. Clin. Exp. Dermatol. 31, 611–612 80. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune (2006). responses. Nat. Immunol. 5, 987–995 (2004). 55. Chan, P. K., Ng, B. K. & Wong, C. Y. Bacille Calmette-Guérin osteomyelitis of the 81. von Meyenn, F. et al. Toll-like receptor 9 contributes to recognition of Myco- proximal femur. Hong. Kong Med. J. 16, 223–226 (2010). bacterium bovis Bacillus Calmette-Guérin by Flt3-ligand generated dendritic 56. Gharehdaghi, M., Hassani, M., Ghodsi, E., Khooei, A. & Moayedpour, cells. Immunobiology 211, 557–565 (2006). A. Bacille Calmette-Guérin osteomyelitis. Arch. Bone Jt. Surg. 3, 291–295 82. Bafica, A. et al. TLR9 regulates Th1 responses and cooperates with TLR2 in (2015). mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 202, 57. Atikan, B. Y., Cavusoglu, C., Dortkardesler, M. & Sozeri, B. Assessment of tuber- 1715–1724 (2005). culosis infection during treatment with biologic agents in a BCG-vaccinated 83. Gagliardi, M. C. et al. Mycobacterium bovis Bacillus Calmette-Guerin infects DC- pediatric population. Clin. Rheumatol. 35, 427–431 (2016). SIGN- dendritic cell and causes the inhibition of IL-12 and the enhancement of 58. Lotte, A. et al. Second IUATLD study on complications induced by intradermal IL-10 production. J. Leukoc. Biol. 78, 106–113 (2005). BCG-vaccination. Bull. Int. Union Tuberc. Lung Dis. 63,47–59 (1988). 84. Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 59. Marciano, B. E. et al. BCG vaccination in patients with severe combined enhances systemic innate immunity. Nat. Med. 16, 228–231 (2010). immunodeficiency: complications, risks, and vaccination policies. J. Allergy Clin. 85. Kaufmann, S. H. Tuberculosis vaccines: time to think about the next generation. Immunol. 133, 1134–1141 (2014). Semin. Immunol. 25, 172–181 (2013). 60. Mahmoudi, S. et al. Adverse reactions to Mycobacterium bovis bacille Calmette- 86. Bollampalli, V. P. et al. BCG skin infection triggers IL-1R-MyD88-dependent Guérin vaccination against tuberculosis in Iranian children. Clin. Exp. Vaccine Res. migration of EpCAMlow CD11bhigh skin dendritic cells to draining lymph node 4, 195–199 (2015). during CD4 + T-cell priming. PLoS Pathog. 11, e1005206 (2015).

Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021) 14 J. Li et al. 10 87. Bizzell, E. et al. Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T 114. Lertmemongkolchai, G., Cai, G., Hunter, C. A. & Bancroft, G. J. Bystander acti- cell responses. J. Leukoc. Biol. 103, 739–748 (2018). vation of CD8 + T cells contributes to the rapid production of IFN-gamma in 88. Su, H., Peng, B., Zhang, Z., Liu, Z. & Zhang, Z. The Mycobacterium tuberculosis response to bacterial pathogens. J. Immunol. 166, 1097–1105 (2001). glycoprotein Rv1016c protein inhibits dendritic cell maturation, and impairs Th1 115. Conrath, U. Systemic acquired resistance. Plant Signal. Behav. 1, 179–184 (2006). /Th17 responses during mycobacteria infection. Mol. Immunol. 109,58–70 116. Pham, L. N., Dionne, M. S., Shirasu-Hiza, M. & Schneider, D. S. A specific primed (2019). immune response in Drosophila is dependent on phagocytes. PLoS Pathog. 3, 89. Bertholet, S. et al. Identification of human T cell antigens for the development of e26 (2007). vaccines against Mycobacterium tuberculosis. J. Immunol. 181, 7948–7957 117. Rodrigues, J., Brayner, F. A., Alves, L. C., Dixit, R. & Barillas-Mury, C. Hemocyte (2008). differentiation mediates innate immune memory in Anopheles gambiae mos- 90. Andersen, P. & Kaufmann, S. H. Novel vaccination strategies against tuberculosis. quitoes. Science 329, 1353–1355 (2010). Cold Spring Harb. Perspect. Med. 4. https://doi.org/10.1101/cshperspect.a018523 118. Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer (2014). cells. Nature 457, 557–561 (2009). 91. Rossouw, M., Nel, H. J., Cooke, G. S., van Helden, P. D. & Hoal, E. G. Association 119. Quintin, J. et al. Candida albicans infection affords protection against reinfection between tuberculosis and a polymorphic NFkappaB binding site in the inter- via functional reprogramming of monocytes. Cell Host Microbe 12, 223–232 feron gamma gene. Lancet (Lond., Engl.) 361, 1871–1872 (2003). (2012). 92. Morel, C. et al. Mycobacterium bovis BCG-infected neutrophils and dendritic 120. Kleinnijenhuis, J., van Crevel, R. & Netea, M. G. Trained immunity: consequences cells cooperate to induce specific T cell responses in humans and mice. Eur. J. for the heterologous effects of BCG vaccination. Trans. R. Soc. Tropical Med. Hyg. Immunol. 38, 437–447 (2008). 109,29–35 (2015). 93. Hanekom, W. A. The immune response to BCG vaccination of newborns. Ann. N. 121. Covián, C. et al. BCG-induced cross-protection and development of trained Y. Acad. Sci. 1062,69–78 (2005). immunity: implication for vaccine design. Front. Immunol. 10, 2806 (2019). 94. Soares, A. P. et al. Longitudinal changes in CD4( + ) T-cell memory responses 122. Wen, H., Dou, Y., Hogaboam, C. M. & Kunkel, S. L. Epigenetic regulation of induced by BCG vaccination of newborns. J. Infect. Dis. 207,1084–1094 dendritic cell-derived interleukin-12 facilitates immunosuppression after a (2013). 92. severe innate immune response. Blood 111, 1797–1804 (2008). 95. Murray, R. A. et al. Bacillus Calmette Guerin vaccination of human newborns 123. Foster, S. L. & Medzhitov, R. Gene-specific control of the TLR-induced inflam- induces a specific, functional CD8 + T cell response. J. Immunol. 177, 5647–5651 matory response. Clin. Immunol. 130,7–15 (2009). (2006). 93. 124. Doñas, C. et al. Trichostatin A promotes the generation and suppressive func- 96. Mosmann, T. R. & Coffman, R. L. TH1 and TH2 cells: different patterns of lym- tions of regulatory T cells. Clin. Dev. Immunol. 2013, 679804 (2013). phokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 125. Zhang, Q. & Cao, X. Epigenetic regulation of the innate immune response to 145–173 (1989). infection. Nat. Rev. Immunol. 19, 417–432 (2019). 97. Li, H. & Javid, B. Antibodies and tuberculosis: finally coming of age?. Nat. Rev. 126. Arts, R. J. et al. Long-term in vitro and in vivo effects of γ-irradiated BCG on Immunol. 18, 591–596 (2018). innate and adaptive immunity. J. Leukoc. Biol. 98, 995–1001 (2015). 98. Kozakiewicz, L. et al. B cells regulate neutrophilia during Mycobacterium 127. Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection tuberculosis infection and BCG vaccination by modulating the interleukin-17 in humans through the induction of cytokines associated with trained immu- response. PLoS Pathog. 9, e1003472 (2013). nity. Cell Host Microbe 23,89–100 e105 (2018). 99. Sebina, I. et al. Long-lived memory B-cell responses following BCG vaccination. 128. Ifrim, D. C. et al. Candida albicans primes TLR cytokine responses through a PloS ONE 7, e51381 (2012). Dectin-1/Raf-1-mediated pathway. J. Immunol. 190, 4129–4135 (2013). 100. Chen, T. et al. Association of human antibodies to arabinomannan with 129. Cheng, S. C. et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic enhanced mycobacterial opsonophagocytosis and intracellular growth reduc- basis for trained immunity. Science 345, 1250684 (2014). tion. J. Infect. Dis. 214, 300–310 (2016). 130. Arts, R. J. et al. Glutaminolysis and fumarate accumulation integrate immuno- 101. Sánchez-Rodríguez, C. et al. An IgG antibody response to the metabolic and epigenetic programs in trained immunity. Cell Metab. 24, antigen 85 complex is associated with good outcome in Mexican Totonaca 807–819 (2016). Indians with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 6, 131. Saz-Leal, P. et al. Targeting SHIP-1 in myeloid cells enhances trained immunity 706–712 (2002). and boosts response to infection. Cell Rep. 25, 1118–1126 (2018). 102. Costello, A. M. et al. Does antibody to mycobacterial antigens, including 132. Domínguez-Andrés, J. et al. The itaconate pathway is a central regulatory node lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans. R. Soc. linking innate immune tolerance and trained immunity. Cell Metab. 29, 211–220. Trop. Med. Hyg. 86, 686–692 (1992). e215 (2019). 103. Lu, L. L. et al. A functional role for antibodies in tuberculosis. Cell 167, 433–443 133. Bekkering, S. et al. Metabolic induction of trained immunity through the e414 (2016). mevalonate pathway. Cell 172, 135–146. e139 (2018). 104. Uranga, S., Marinova, D., Martin, C. & Aguilo, N. Protective efficacy and pul- 134. Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differ- monary immune response following subcutaneous and intranasal BCG admin- entiation and trained innate immunity. Science 345, 1251086 (2014). istration in mice. J. Vis. Exp. https://doi.org/10.3791/54440 (2016). 135. Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate pro- 105. Hansen, I. S., Baeten, D. L. P. & den Dunnen, J. The inflammatory function of tective innate immunity against tuberculosis. Cell 172, 176–190. e119 (2018). human IgA. Cell Mol. Life Sci. 76, 1041–1055 (2019). 136. Guerra-Maupome, M., Vang, D. X. & McGill, J. L. Aerosol vaccination with Bacille 106. Welsh, R. M. & Selin, L. K. No one is naive: the significance of heterologous T-cell Calmette-Guerin induces a trained innate immune phenotype in calves. PloS immunity. Nat. Rev. Immunol. 2, 417–426 (2002). ONE 14, e0212751 (2019). 107. Netea, M. G., Quintin, J. & van der Meer, J. W. Trained immunity: a memory for 137. de Bree, L. C. J. et al. Bacillus Calmette-Guérin-induced trained immunity is not innate host defense. Cell Host Microbe 9, 355–361 (2011). protective for experimental influenza A/Anhui/1/2013 (H7N9) infection in mice. 108. Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent non- Front. Immunol. 9, 869 (2018). specific protection from reinfection via epigenetic reprogramming of mono- 138. WHO. Bacille Calmette-Guerin (BCG) vaccination and COVID-19. www.who.int/ cytes. Proc. Natl. Acad. Sci. USA 109, 17537–17542 (2012). news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)- 109. Djuardi, Y., Sartono, E., Wibowo, H., Supali, T. & Yazdanbakhsh, M. A longitudinal vaccination-and-covid-19 (2020). study of BCG vaccination in early childhood: the development of innate and 139. Nykopp, T. K., Batista da Costa, J., Mannas, M. & Black, P. C. Current Clinical Trials adaptive immune responses. PloS ONE 5, e14066 (2010). in non-muscle invasive bladder cancer. Curr. Urol. Rep. 19, 101 (2018). 110. Mathurin, K. S., Martens, G. W., Kornfeld, H. & Welsh, R. M. CD4 T-cell-mediated 140. Fuge, O., Vasdev, N., Allchorne, P. & Green, J. S. Immunotherapy for bladder heterologous immunity between mycobacteria and poxviruses. J. Virol. 83, cancer. Res. Rep. Urol. 7,65–79 (2015). 3528–3539 (2009). 141. Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder 111. Kleinnijenhuis, J. et al. Long-lasting effects of BCG vaccination on both het- cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314–2330 (2007). erologous Th1/Th17 responses and innate trained immunity. J. Innate Immun. 6, 142. Zhang, J. et al. Management of non-muscle-invasive bladder cancer: quality of 152–158 (2014). clinical practice guidelines and variations in recommendations. BMC Cancer 19, 112. Berg, R. E., Cordes, C. J. & Forman, J. Contribution of CD8 + T cells to innate 1054 (2019). immunity: IFN-gamma secretion induced by IL-12 and IL-18. Eur. J. Immunol. 32, 143. Burger, M. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non- 2807–2816 (2002). muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63,36–44 (2013). 113. Berg, R. E., Crossley, E., Murray, S. & Forman, J. Memory CD8 + T cells provide 144. Kamat, A. M. et al. Expert consensus document: consensus statement on best innate immune protection against Listeria monocytogenes in the absence of practice management regarding the use of intravesical immunotherapy with cognate antigen. J. Exp. Med. 198, 1583–1593 (2003). BCG for bladder cancer. Nat. Rev. Urol. 12, 225–235 (2015).

npj Vaccines (2021) 14 Published in partnership with the Sealy Institute for Vaccine Sciences J. Li et al. 11 145. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of 166. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. & Smyth, J. F. the bladder: update 2016. Eur. Urol. 71, 447–461 (2017). Intravesical Evans strain BCG therapy: quantitative immunohistochemical 146. Böhle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. & Flad, H. D. Effects of local analysis of the immune response within the bladder wall. J. Urol. 147, bacillus Calmette-Guerin therapy in patients with bladder carcinoma on 1636–1642 (1992). immunocompetent cells of the bladder wall. J. Urol. 144,53–58 (1990). 167. Suttmann, H., Lehan, N., Böhle, A. & Brandau, S. Stimulation of neutrophil 147. Kavoussi, L. R., Brown, E. J., Ritchey, J. K. & Ratliff, T. L. Fibronectin-mediated granulocytes with Mycobacterium bovis bacillus Calmette-Guérin induces Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement changes in phenotype and gene expression and inhibits spontaneous apop- for the expression of an antitumor response. J. Clin. Investig. 85,62–67 (1990). tosis. Infect. Immun. 71, 4647–4656 (2003). 148. Maksymowych, W. P. & Kane, K. P. Bacterial modulation of antigen processing 168. Ratliff, T. L., Gillen, D. & Catalona, W. J. Requirement of a thymus dependent and presentation. Microbes Infect. 2, 199–211 (2000). immune response for BCG-mediated antitumor activity. J. Urol. 137, 155–158 149. De Boer, E. C. et al. Presence of activated lymphocytes in the urine of patients (1987). with superficial bladder cancer after intravesical immunotherapy with bacillus 169. Saint, F. et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical Calmette-Guérin. Cancer Immunol. Immunother. 33, 411–416 (1991). BCG maintenance therapy for superficial bladder cancer. Urology 57, 617–621 150. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. & Smyth, J. F. Radio- (2001). immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J. Urol. 144, 1248–1251 (1990). 151. Nadler, R. et al. Interleukin 10 induced augmentation of delayed-type hyper- ACKNOWLEDGEMENTS sensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) This work was supported by National Science and Technology Major Project for 131 – mediated antitumour activity. Clin. Exp. Immunol. , 206 216 (2003). Infectious Diseases Control and Prevention (2017ZX10304402-001-016) and CAMS 152. de Reijke, T. M. et al. Cytokine production by the human bladder carcinoma cell Major Innovation Funding for Medical Science (2016-I2M-1-013). line T24 in the presence of bacillus Calmette-Guerin (BCG). Urol. Res. 21, 349–352 (1993). 153. de Boer, E. C. et al. Role of interleukin-8 in onset of the immune response in AUTHOR CONTRIBUTIONS intravesical BCG therapy for superficial bladder cancer. Urol. Res. 25,31–34 (1997). 154. De Boer, E. C. et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour J.L. and C.Q. conceived the project direction; J.L. researched and collated all the necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in relevant literature; L.Z. and C.Q. revised and edited the manuscript; J.L. wrote the superficial bladder cancer. Cancer Immunol. Immunother. 34,306–312 (1992). manuscript. 155. Esuvaranathan, K. et al. Interleukin-6 production by bladder tumors is upregu- lated by BCG immunotherapy. J. Urol. 154, 572–575 (1995). COMPETING INTERESTS 156. Pichler, R. et al. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in blad- The authors declare no competing interests. der cancer. Oncotarget 7, 39916–39930 (2016). 157. Lage, J. M., Bauer, W. C., Kelley, D. R., Ratliff, T. L. & Catalona, W. J. Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette- ADDITIONAL INFORMATION fi 135 – Guerin treatment of super cial bladder cancer. J. Urol. , 916 919 (1986). Correspondence and requests for materials should be addressed to L.Z. or C.Q. 158. Alexandroff, A., Jackson, A., Skibinska, A. & James, K. Production of IL-5, a clas- sical T(H)2 cytokine, following bacillus Calmette guerin immunotherapy of Reprints and permission information is available at http://www.nature.com/ 9 – bladder cancer. Int. J. Oncol. , 179 182 (1996). reprints 159. O’Donnell, M. A. et al. Role of IL-12 in the induction and potentiation of IFN-gamma 163 – in response to bacillus Calmette-Guérin. J. Immunol. ,4246 4252 (1999). Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims 160. Jackson, A. M. et al. Changes in urinary cytokines and soluble intercellular in published maps and institutional affiliations. adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calm- ette-Guérin (BCG) immunotherapy. Clin. Exp. Immunol. 99, 369–375 (1995). 161. Eto, M. et al. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors. Urol. Int. 75, Open Access This article is licensed under a Creative Commons 114–118 (2005). Attribution 4.0 International License, which permits use, sharing, 162. Luo, Y., Chen, X. & O’Donnell, M. A. Mycobacterium bovis bacillus Calmette- adaptation, distribution and reproduction in any medium or format, as long as you give Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin. appropriate credit to the original author(s) and the source, provide a link to the Creative Exp. Immunol. 147, 370–378 (2007). Commons license, and indicate if changes were made. The images or other third party 163. de Boer, E. C. et al. Leukocytes in the urine after intravesical BCG treatment material in this article are included in the article’s Creative Commons license, unless for superficial bladder cancer. A flow cytofluorometric analysis. Urol. Res. 19, indicated otherwise in a credit line to the material. If material is not included in the 45–50 (1991). article’s Creative Commons license and your intended use is not permitted by statutory 164. Ludwig, A. T. et al. Tumor necrosis factor-related apoptosis-inducing ligand: a regulation or exceeds the permitted use, you will need to obtain permission directly novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. from the copyright holder. To view a copy of this license, visit http://creativecommons. Cancer Res. 64, 3386–3390 (2004). org/licenses/by/4.0/. 165. Suttmann, H. et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66, 8250–8257 (2006). © The Author(s) 2021

Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021) 14